Melinta Therapeutics will be making presentations at ASM Microbe 2016 in Boston June 16-20, including posters on Baxdela™ (delafloxacin), an investigational anionic quinolone being assessed for the treatment of patients with serious bacterial infections.

Melinta will also present results from preclinical studies from its ESKAPE Pathogen Program, which aims to introduce completely novel classes of antibiotics to meet the challenge posed by the emergence of multi-drug-resistant and extensively drug-resistant bacteria.

In addition, Chief Scientific Officer Erin Duffy, Ph.D. will present “U.S. Experiences in Antibiotic Development” during a Meet-the-Experts session.